Literature DB >> 30481368

Melanoma of unknown primary.

Yun Song1, Giorgos C Karakousis2.   

Abstract

Formally described in the 1960s, melanoma of unknown primary (MUP) is characterized by the finding of metastatic melanoma within the lymph nodes, subcutaneous tissues, and other distant sites without an evident primary lesion. The most likely hypothesis of its etiology is an immune-mediated regression of the primary after metastasis has occurred. In addition, patients with MUP appear to have equivalent or better outcomes compared with patients with known primaries of a similar stage.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  malignant melanoma; melanoma occult primary; melanoma regression; unknown primary

Mesh:

Year:  2018        PMID: 30481368     DOI: 10.1002/jso.25302

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

1.  Multidisciplinary Care for Melanoma of Unknown Primary: Experience in the Era of Molecular Profiling.

Authors:  James P De Andrade; Paul Wong; Michael P O'Leary; Vishwas Parekh; Arya Amini; Hans F Schoellhammer; Kim A Margolin; Michelle Afkhami; Laleh G Melstrom
Journal:  Ann Surg Oncol       Date:  2020-09-09       Impact factor: 5.344

2.  Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results.

Authors:  Thilo Gambichler; Maria Chatzipantazi; Ulrike Schröter; E Stockfleth; Cansu Gedik
Journal:  Oncoimmunology       Date:  2019-10-21       Impact factor: 8.110

3.  Metastatic melanoma of unknown origin mimicking neurofibromatosis.

Authors:  Lauren Chen; Celeste Newby; Nibras Fakhri; Markus Lammle
Journal:  Radiol Case Rep       Date:  2020-11-10

4.  Melanoma metastasis mimicking gastric cancer: a challenge that starts from diagnosis.

Authors:  Manlio Monti; Massimo Guidoboni; Devil Oboldi; Giulia Bartolini; Federica Pieri; Silvia Ruscelli; Alessandro Passardi; Laura Ridolfi; Francesco De Rosa; Francesco Giulio Sullo; Giovanni Luca Frassineti
Journal:  Therap Adv Gastroenterol       Date:  2021-02-24       Impact factor: 4.409

5.  Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy.

Authors:  Danielle Verver; Dirk J Grünhagen; Alexander C J van Akkooi; Maureen J B Aarts; Franchette W P J van den Berkmortel; Alfonsus J M van den Eertwegh; Jan Willem B de Groot; Marye J Boers-Sonderen; John B A G Haanen; Geke A P Hospers; Ellen Kapiteijn; Djura Piersma; Rozemarijn S van Rijn; Karijn P M Suijkerbuijk; Albert J Ten Tije; Gerard Vreugdenhil; Cornelis Verhoef; Astrid A M van der Veldt
Journal:  Cancer Immunol Immunother       Date:  2021-03-27       Impact factor: 6.968

6.  Hypothesised cutaneous sites of origin of stage III melanomas with unknown primary: A multicentre study.

Authors:  Bethan Clayton; Ferhan Muneeb; Maria Celia B Hughes; Megan E Grant; Kiarash Khosrotehrani; B Mark Smithers; Romina Spina; Luca G Campana; Deemesh Oudit; Adele C Green
Journal:  Int J Cancer       Date:  2022-04-25       Impact factor: 7.316

7.  Melanoma of unknown primary in the pancreas: should it be considered primary?

Authors:  Yanwen Jin; Congdun Ran; Fuyu Li; Nansheng Cheng
Journal:  BMC Surg       Date:  2020-04-16       Impact factor: 2.102

8.  Overexpression of RACK1 Predicts Poor Prognosis in Melanoma.

Authors:  Congcong Shen; Hui Hua; Lixiong Gu; Shuanglin Cao; Hengji Cai; Xiaodong Yao; Xiaodong Chen
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.